ZeaVaxx


ZEAVAXX LLC is an Indiana-based animal healthcare company dedicated to improving current animal vaccines through a plant-derived nanoparticle adjuvant platform. Their proprietary platform, Zea-11, is a glucan-based nanoparticle derived from plants, designed to enhance vaccine efficacy. Founded by experts from Purdue University, the company aims to revolutionize veterinary vaccines with innovative technology.

Industries

animal-feed
biotechnology
medical
veterinary

Nr. of Employees

small (1-50)

ZeaVaxx

Purdue Railyard, 1281 Win Hentschel Blvd., West Lafayette, IN 47906, USA


Products

Plant-derived glucan-based nanoparticle adjuvant

A glucan-based nanoparticle material extracted from plants and chemically functionalized for use as an adjuvant in animal vaccine formulations; positioned as a cost-feasible alternative to traditional aluminum-containing adjuvants.


Services

Licensing the plant-derived nanoparticle adjuvant platform to animal healthcare and vaccine companies for integration into vaccine product lines.

Development of proprietary animal vaccine candidates that incorporate the plant-derived nanoparticle adjuvant platform.

Expertise Areas

  • Animal vaccine development
  • Adjuvant development
  • Nanoparticle formulation
  • Vaccine formulation and compatibility
  • Show More (3)

Key Technologies

  • Plant-derived glucan nanoparticles
  • Nanoparticle-based adjuvants
  • Chemical functionalization of biomaterials
  • Vaccine formulation methods
  • Show More (1)

News & Updates

ZeaVaxx was awarded the 3rd place of the Gold Division.

ZeaVaxx was awarded the Black Award.

ZeaVaxx was named one of the finalists.

ZeaVaxx participated in the NSF I-Corps program.

ZeaVaxx will present at the Ag Tech Investor Conference 2017 in Des Moines, IA.

Zea-11 patent was granted by USPTO.

View All News

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.